Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een open-label-extensiestudie van ORKA-001 bij deelnemers met plaque psoriasis

21 oktober 2026 bijgewerkt door: Oruka Therapeutics, Inc.

Een open-label vervolgstudie om de langetermijnveiligheid, verdraagbaarheid en werkzaamheid van ORKA-001 te evalueren bij deelnemers met matige tot ernstige plaque psoriasis

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.

Studietype

Ingrijpend

Inschrijving (Geschat)

240

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Alberta
      • Edmonton, Alberta, Canada, T5J 3S9
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Edmonton, Alberta, Canada, T6G 1C3
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • British Columbia
      • Surrey, British Columbia, Canada, V3R 6A7
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Surrey, British Columbia, Canada, V3V 0C6
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B IG9
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Ontario
      • Ajax, Ontario, Canada, L1S7K8
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • London, Ontario, Canada, N6H 5L5
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Markham, Ontario, Canada, L3P 1X3
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Peterborough, Ontario, Canada, K9J 5K2
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Toronto, Ontario, Canada, M4W 2N4
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Waterloo, Ontario, Canada, N2J 1C4
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Quebec
      • Montreal, Quebec, Canada, H2X2V1
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Québec, Quebec, Canada, G1V4X7
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85032
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Arkansas
      • North Little Rock, Arkansas, Verenigde Staten, 72117
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • California
      • Fountain Valley, California, Verenigde Staten, 92708
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Los Angeles, California, Verenigde Staten, 90045
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Los Angeles, California, Verenigde Staten, 90095
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • San Diego, California, Verenigde Staten, 92123
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Santa Ana, California, Verenigde Staten, 92701
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Santa Monica, California, Verenigde Staten, 90403
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Connecticut
      • Cromwell, Connecticut, Verenigde Staten, 06416
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Florida
      • Miami, Florida, Verenigde Staten, 33126
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Illinois
      • Rolling Meadows, Illinois, Verenigde Staten, 60008
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Indiana
      • Plainfield, Indiana, Verenigde Staten, 46168
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Kentucky
      • Bowling Green, Kentucky, Verenigde Staten, 42104
    • Maryland
      • Rockville, Maryland, Verenigde Staten, 20850
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02111
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Michigan
      • Detroit, Michigan, Verenigde Staten, 48202
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • New York
      • New York, New York, Verenigde Staten, 10023
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • New York, New York, Verenigde Staten, 10029
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44106
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Mason, Ohio, Verenigde Staten, 45040
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97201
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Portland, Oregon, Verenigde Staten, 97210
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Texas
      • Frisco, Texas, Verenigde Staten, 75033
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Houston, Texas, Verenigde Staten, 77004
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
      • Webster, Texas, Verenigde Staten, 77598
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:
    • Virginia
      • Norfolk, Virginia, Verenigde Staten, 23502
        • Werving
        • Oruka Therapeutics Investigative Site
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Signed informed consent by participants from previous trial choosing to transition into the OLE.
  2. Participants who have successfully completed the preceding trial.
  3. For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
  4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception

Exclusion Criteria:

  1. Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
  2. Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
  3. Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
  4. Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
  5. Participant is pregnant or breastfeeding.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: ORKA-001 Once Yearly (High Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Experimenteel: ORKA-001 Once Yearly (Low Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Experimenteel: ORKA-001 Twice Yearly

Participants will receive ORKA-001 every 6 months per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Geen tussenkomst: No Drug

Participants will receive no drug until protocol defined PASI response criterion is met.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Tijdsspanne: Day 1 through Week 144

Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.

Day 1 through Week 144

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tijdsspanne: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tijdsspanne: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tijdsspanne: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tijdsspanne: Time Frame: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Time Frame: Day 1 through Week 96
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Tijdsspanne: Day 1 through Week 96

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Tijdsspanne: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Tijdsspanne: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
PASI Score Over Time
Tijdsspanne: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
IGA Score Over Time
Tijdsspanne: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

23 februari 2026

Primaire voltooiing (Geschat)

1 mei 2030

Studie voltooiing (Geschat)

1 juli 2030

Studieregistratiedata

Eerst ingediend

26 februari 2026

Eerst ingediend dat voldeed aan de QC-criteria

26 februari 2026

Eerst geplaatst (Werkelijk)

4 maart 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

23 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

21 oktober 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • ORKA-001-113

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .